# Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

> **NCT03715478** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Myeloma Research Group** · enrollment: 120 (estimated)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** GSK2857916 with Pomalidomide and Dexamethasone

## Key facts

- **NCT ID:** NCT03715478
- **Lead sponsor:** Canadian Myeloma Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-26
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715478, "Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03715478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*